Title	First International Moxifloxacin Symposium [electronic resource] : Berlin, 1999 / edited by Lionel Mandell
Imprint	Berlin, Heidelberg : Springer Berlin Heidelberg, 2000
Connect to	http://dx.doi.org/10.1007/978-3-642-59681-0
Descript	XIII, 191 p. online resource

The proceedings of this symposium focus on the new and exciting fluoroquinolone Moxifloxacin. Physicians/scientists from around the world have contributed to this effort and the information in these proceedings has been organized as follows: Part I: Antimicrobial Chemotherapy Part II: Preclinical Microbiology Part III: Pharmacology Part IV: Clinical Needs in the Millenium Part V: Round Table Discussion It is hoped that the reader will gain an appreciation of the various basic and clinical issues pertaining to the fluoroquinolones in general and moxifloxacin in particular and the role of this agent in the management of respiratory tract infections

to the Symposium -- 1 โ{128}{148} Antimicrobial Chemotherapy -- Antimicrobial Chemotherapy โ{128}{148} Today -- Antimicrobial Chemotherapy โ{128}{148} Tomorrow -- PART2โ{128}{148}Pre-clinical -- Pre-clinical Microbiology โ{128}{148} Streptococcus Pneumoniae -- Pre-clinical Microbiology โ{128}{148} Gram-positive Cocci -- Pre-clinical Microbiology โ{128}{148} Atypical Organisms -- Pre-clinical Microbiology โ{128}{148} Summary I -- Pre-clinical Microbiology โ{128}{148} Mycobacteria -- In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria -- Pre-clinical Microbiology โ{128}{148} Fastidious Gram-negative Bacteria -- Pre-clinical Microbiology โ{128}{148} Respiratory Tract Infections Susceptibility Survey โ{128}{148} USA -- Pre-clinical Microbiology โ{128}{148} Respiratory Tract Infections Susceptibility Survey โ{128}{148} Europe -- Pre-clinical Microbiology โ{128}{148} Respiratory Tract Infections Susceptibility Survey โ{128}{148} Japan -- Mechanisms of Fluoroquinolone Action and Resistance -- Pre-clinical Microbiology โ{128}{148} Summary II -- 3 โ{128}{148} Pharmacology -- Pharmacokinetics and Pharmacodynamics of Antimicrobials -- Mini-Reviews โ{128}{148} Pharmacokinetics/Pharmacodynamics (PK/PD) -- In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones -- In vitro Models of Infection โ{128}{148} Pharmacokinetic/Pharmacodynamic Correlates -- Animal Model Experiences with Moxifloxacin -- Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials -- Pharmacology of Moxifloxacin โ{128}{148} Absorption, Distribution, Metabolism and Excretion -- Antimicrobial Drug-Drug Interations โ{128}{148} Focus on Fluoroquinolones -- Pharmacology โ{128}{148} Tissue Distribution -- Fluoroquinolones Phototoxicity โ{128}{148} Moxifloxacin in Context -- Fluoroquinolone Safety and Tolerability -- 4 โ{128}{148} Clinical Needs in the Millenium -- Clinical Needs in the Millenium โ{128}{148} Community Acquired Pneumonia -- Clinical Needs in the Millenium โ{128}{148} Pneumonia โ{128}{148} The Role of Moxifloxacin -- Clinical Needs in the Millenium โ{128}{148} Acute Exacerbations of Chronic Bronchitis -- Clinical Needs in the Millenium โ{128}{148} Acute Exacerbations of Chronic Bronchitis โ{128}{148} The Role of Moxifloxacin -- Clinical Needs in the Millenium โ{128}{148} Rhinosinusitis -- Clinical Needs in the Millenium โ{128}{148} Rhinosinusitis โ{128}{148} The Role of Moxifloxacin -- Discussion on Clinical Needs in the Millenium -- 5 โ{128}{148} Round Table Discussion -- Round Table Discussion โ{128}{148} Introduction -- Round Table Discussion โ{128}{148} Hospital Issues -- Round Table Discussion โ{128}{148} Community Issues